A Phase 1/2 Open-Label, Multicenter Study to Characterize the Safety and Tolerability of CFT8634 in Subjects With Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Type of Study

Treatment

Locations

CTRC Inpatient
Outpatient CTRC
University of Colorado Hospital

Principal Investigator
Photograph of Anthony Elias,  MD

Anthony Elias, MD

Study ID

Protocol Number: 22-0052

More information available at ClinicalTrials.gov: NCT05355753

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers